Two weeks ago, Jeff Martin came aboard Rothschild as a managing director in the firm’s corporate finance group. In addition to working on general M&A, Martin said he would focus on healthcare and lend a hand to Rothschild’s restructuring practice. Prior to joining Rothschild, Martin oversaw San Francisco-based Thomas Weisel Partners LLC’s East Coast M&A practice, where he focused on the life-sciences segment of healthcare. He anticipates continued M&A activity there and pointed to Vertex Pharmaceuticals Inc.’s planned $554 million stock acquisition of Aurora Biosciences Corp., announced two weeks ago, as an example.
To read the entire story, you must be logged in.
Please log in now or register with us.
